Friday, 13 October 2017

08.45 – 09.00 Opening and objectives
C. Chapple, Sheffield (GB)
F. Cruz, Porto (PT)
R. Djinovic, Belgrade (RS)

09.00 – 09.30 State-of-the-art lecture:
Can OAB be a consequence of an unrecognised urinary infection?
Chair: C. Chapple, Sheffield (GB)
For: A. Tubaro, Rome (IT)
Against: F. Van Der Aa, Leuven (BE)

09.30 – 11.00 Why do clinical trials not correlate with real life clinical practice?
Chair: C. Chapple, Sheffield (GB)

09.30 – 09.35 Setting the scene
C. Chapple, Sheffield (GB)

09.35 – 09.50 What are the options for OAB patients with partial response to antimuscarinics?
F. Van Der Aa, Leuven (BE)

09.50 – 10.05 Are beta 3 agonists ready to be first line option?
P. Van Kerrebroeck, Maastricht (NL)

10.05 – 10.20 OAB refractory to oral medication: Botulinum toxin or sacral neuromodulation?
S. Arlandis, Valencia (ES)

10.20 – 10.35 OAB treatment in elderly patients
M. Kirby, Baldock (GB)

10.35 – 10.50 Interactive clinical case discussion
All faculty

10.50 – 11.00 Take home message
C. Chapple, Sheffield (GB)

11.00 – 11.30 Coffee break

11.30 – 12.00 Why is low persistence on treatment a problem for OAB patients?
Chair: F. Cruz, Porto (PT)
Discussant: A. Wagg, Alberta (CA)

12.00 – 13.00 The Underactive Bladder
Chair: P. Van Kerrebroeck, Maastricht (NL)

12.00 - 12.20 Consensus report on definition
P. Van Kerrebroeck, Maastricht (NL)

12.20 - 12.40 Therapeutic options
A. Stenzl, Tübingen (DE)

12.40 – 13.00 Case discussion and take home messages
G. Van Koeveringe, Maastricht (NL)

13.00 – 14.00 Lunch & Industry Session/ Meet the expert
14.00 – 14.30  State-of-the-art lecture: Nocturia affects both men and women!
Case studies – a male patient voiding 4 times a day with nocturia x5 and nocturnal polyuria)
Chair: K-D. Sievert, Salzburg (AT)
Discussant: M.J. Drake, Bristol (GB)

14.30 – 15.30  Female stress urinary incontinence
Chair: F. Cruz, Porto (PT)
14.30 – 14.35  Setting the scene
F. Cruz, Porto (PT)
14.35 – 14.50  Doctor, if I have the operation, will I be cured forever?
Tufan Tarcan, Istanbul (TR)
14.50 – 15.05  Doctor, I had the surgery but I am still leaking
F. Burkhard, Berne (CH)
15.05 – 15.20  Should POP and SIU be corrected at the same time?
E. Costantini, Perugia (IT)
15.20 – 15.30  Discussion and take home messages
F. Cruz, Porto (PT)

15.30 – 16.00  Coffee break

16.00 – 16.30  Quality of Life and its assessment in female urology
State of the Art
Chair: M.J. Drake, Bristol (GB)
I. Milsom, Gothenburg (SE)

Parallel session EUGA
16.30 – 17.30  POP and the use of mesh
Chair: L. Cardozo, London (GB)
16.30 – 16.35  Setting the scene
L. Cardozo, London (GB)
16.35 – 16.45  Pelvic organ prolapse in young women: Which strategy?
B. O’Reilly, Cork (IE)
16.45 – 16.55  Ageing of the pelvic floor
H. Koelbl, Vienna (AT)
16.55 – 17.05  POP surgery. Native tissue repair: Back to the future
S. Salvatore, Milan (IT)
17.05 – 17.15  POP surgery: When and why I choose laparoscopic or vaginal approach
S. Athanasiou, Athens (GR)
17.15 – 17.30  General discussion and take home message
L. Cardozo, London (GB)

Parallel Session  ESGURS
16.30 – 17.30  Peyronie’s disease
Chair: R. Djinovic, Belgrade (RS)
16.30 – 16.35  Setting the scene
R. Djinovic, Belgrade (RS)

16.35 – 16.50  Corporoplasty
N. Tomada, Porto (PT)

16.50 – 17.05  Doctor, I don’t want my penis shortened!
S. Sansalone, Rome (IT)

17.05 – 16.20  When is a penile prosthesis is indicated?
J. Romero-Otero, Madrid (ES)

17.20 – 17.30  Discussion and take home messages
R. Djinovic, Belgrade (RS)

17.30 – 19.00  Industry Session Management of refractory OAB – what is the evidence?

Saturday 14 October 2017

08.00 – 08.30  State-of-the-art lecture: Male incontinence after radical prostatectomy. What should I do?
Chair: C. Chapple, Sheffield (GB)
Speaker: J. Heesakkers, Nijmegen (NL)

08.30 – 10.00  NDO and incontinence
Chair: T. Kessler, Zurich (CH)
08.30 – 08.35  Setting the scene
T. Kessler, Zurich (CH)
08.35 – 08.50  Can I control incontinence with oral medication in MS patients?
R. Hamid, London (GB)
08.50 – 09.05  When is the moment to introduce botulinum toxin in MS patients?
G. Del Popolo, Florence (IT)
09.05 – 09.20  How do I follow-up a patient with NDO and spinal cord injury?
J. N. Panicker, London (GB)
09.20 – 09.35  When do I stop botulinum toxin and offer bladder augmentation?
Tufan Tarcan, Istanbul (TR)
09.35 – 09.55  Interactive clinical case discussion
U. Mehnert, Zurich (CH)
09.55 – 10.00  Take home message
T. Kessler, Zurich (CH)

10.00 – 11.00  Dementia and incontinence
Chair: J. Heesakkers, Nijmegen (NL)
10.00 – 10.05  Setting the scene
J. Heesakkers, Nijmegen (NL)
10.05 – 10.20  Management of urinary incontinence in a patient with Alzheimer’s disease
A. Wagg, Alberta (CA)
10.20 – 10.35  Antimuscarinic drugs and brain damage: What is the risk?
R. Bosch, Utrecht (NL)
10.35 – 10.55  Interactive clinical case discussion
F. Burkhardt, Berne (CH)
10.55 – 11.00  Take home message  
J. Heesakkers, Nijmegen (NL)

Parallel session  ESGURS
08.30 - 11.00  Urethroplasty (semi live surgery)  
Chair: R. Djinovic, Belgrade (RS)

08.30 – 09.00  To transect the urethra or not?  
G. Barbagli, Arezzo (IT)

09.00 – 09.30  Augmentation or Anastomosis in the borderline case  
R. Dahlem, Hamburg (DE)

09.30 – 10.00  Female urethroplasty  
C. Chapple, Sheffield (GB)

10.00 – 10.30  Should we ever use penile skin and when?  
N. Lumen, Ghent (BE)

10.30 – 11.00  Managing the hypospadiac ‘cripple’  
D. Wood, London (GB)

11.00 – 11.30  Coffee Break

11.30 – 11.50  My patient has a urinary Fistula – what should I do?  
State of the Art  
Chair: F. Cruz, Porto (PT)  
Discussant: G. Kasyan, Moscow (RU)

11.50 – 13.15  My BPH patient needs treatment  
Chair: D. Castro Diaz, Tenerife (ES)

11.50 – 11.55  Setting the scene  
D. Castro Diaz, Tenerife (ES)

11.55 - 12.10  One drug, two drugs, three drugs? What the EAU guideline tell us  
M. Oelke, Hanover (DE)

12.10 - 12.25  Antimuscarinics or beta 3 agonists for males with persistent storage LUTS?  
E. Finazzi Agrò, Rome (IT)

12.25 - 12.45  Debate: My BPH patient needs surgery  
I prefer LIFT  
K-D. Sievert, Salzburg (AT) (7+3 minutes)  
TURP is still the gold standard  
P. Radziszewski, Warsaw (PL) (7+3 minutes)

12.45 - 13.15  Interactive clinical case discussion and take home messages  
D. Castro Diaz, Tenerife (ES)

13.15 – 14.15  Lunch & Industry Session/ Meet the expert

14.15 - 14.45  Challenging cases  
State of the Art  
Chair: C. Chapple, Sheffield (GB)
Discussant: P. Abrams, Bristol (GB)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.45 – 16.00</td>
<td><strong>Painful Bladder Syndrome (Interstitial cystitis)</strong></td>
<td>Chair: R. Peeker, Gothenburg (SE)</td>
</tr>
<tr>
<td>14.45 – 14.50</td>
<td>Setting the scene</td>
<td>R. Peeker, Gothenburg (SE)</td>
</tr>
<tr>
<td>14.50 – 15.05</td>
<td>Are we talking about a local or a systemic disease?</td>
<td>J. Sairanen, Helsinki (FI)</td>
</tr>
<tr>
<td>15.05 - 15.20</td>
<td>Do mucosal barrier protectors work?</td>
<td>M. Lazzeri, Florence (IT)</td>
</tr>
<tr>
<td>15.20 -15.35</td>
<td>Is botulinum toxin A the future magic bullet for the management of BPS/IC?</td>
<td>P. Radziszewski, Warsaw (PL)</td>
</tr>
<tr>
<td>15.35 – 15.55</td>
<td>Interactive clinical case discussion</td>
<td>D. S. Engeler, St. Gallen (CH)</td>
</tr>
<tr>
<td>15.55 – 16.00</td>
<td>Take home message</td>
<td>R. Peeker, Gothenburg (SE)</td>
</tr>
</tbody>
</table>

| 16.00 – 16.15 | Closure | C. Chapple, Sheffield (GB) |
|               |         | F. Cruz, Porto (PT) |
|               |         | R. Djinovic, Belgrade (RS) |